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Microengineered cancer-on-a-chip platforms to
study the metastatic microenvironment
R. Portillo-Laraab and N. Annabi*acd
More than 90% of cancer-related deaths can be attributed to the occurrence of metastatic diseases. Re-
cent studies have highlighted the importance of the multicellular, biochemical and biophysical stimuli from
the tumor microenvironment during carcinogenesis, treatment failure, and metastasis. Therefore, there is a
need for experimental platforms that are able to recapitulate the complex pathophysiological features of
the metastatic microenvironment. Recent advancements in biomaterials, microfluidics, and tissue engineer-
ing have led to the development of living multicellular microculture systems, which are maintained in con-
trollable microenvironments and function with organ level complexity. The applications of these “on-chip”
technologies for detection, separation, characterization and three dimensional (3D) propagation of cancer
cells have been extensively reviewed in previous works. In this contribution, we focus on integrative micro-
engineered platforms that allow the study of multiple aspects of the metastatic microenvironment, includ-
ing the physicochemical cues from the tumor associated stroma, the heterocellular interactions that drive
trans-endothelial migration and angiogenesis, the environmental stresses that metastatic cancer cells en-
counter during migration, and the physicochemical gradients that direct cell motility and invasion. We dis-
cuss the application of these systems as in vitro assays to elucidate fundamental mechanisms of cancer
metastasis, as well as their use as human relevant platforms for drug screening in biomimetic microenvi-
ronments. We then conclude with our commentaries on current progress and future perspectives of
microengineered systems for fundamental and translational cancer research.
1. Introduction
Cancer refers to a group of remarkably heterogeneous dis-
eases that are characterized by the uncontrolled growth and
spread of abnormal cells. According to estimates from the
International Agency for Research on Cancer, by 2030 both
the global incidence and the mortality rates associated with
cancer will rise to 22 million new cases, and 13 million
deaths per year, respectively.1 In recent years, the develop-
ment of novel immunotherapies and molecularly-targeted
agents, has improved prognosis in patients diagnosed with
cancer.2,3 As cancer treatments shift from non-specific thera-
pies to more personalized approaches, two aspects that will
be crucial for effective therapeutic intervention are: (i) the
substantial intra- and inter-tumor heterogeneity that impact
all of the clinical aspects of the disease,4,5 and (ii) the influ-
ence of the physical and biochemical features of the tumor
microenvironment.6 Moreover, the interaction between pri-
mary tumors with the local microenvironment constitutes
just one aspect of this systemic disease. In fact, malignant tu-
mors shed huge numbers of cancer cells into the blood and
lymphatic vessels, which can spread to distant sites and de-
velop into clinically-relevant metastases.4
Despite great advances in understanding the molecular
and cellular biology of cancer, metastases are still responsible
for over 90% of the mortality in these patients.7 Hence, sev-
eral experimental models have been engineered to reproduce
and study the complexity of the metastatic process. However,
conventional in vitro models are largely unable to accurately
mimic the in vivo setting.8,9 In addition, animal models often
fail to predict drug efficacy in humans.10–12 More recently,
microengineered systems have emerged as powerful tools to
study complex biological phenomena in vitro.13,14 These novel
experimental platforms can be engineered to incorporate bio-
materials that resemble physiological biochemistries and ge-
ometries, as well as microfluidic channel networks that mimic
the transport of fluids and soluble factors across the vascula-
ture.15 Thus, these “on-chip” systems can be used to recreate
the critical cell–cell interfaces, spatiotemporal gradients, and
dynamics of the tumor microenvironment, with a level of ac-
curacy that cannot be achieved by conventional models.16
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In this review, we will discuss the most recent advance-
ments in microengineered models of the metastatic microenvi-
ronment, generated through the integration of micro-
fluidics, biomaterials, and tissue engineering approaches. We
first give an overview of the events by which invasive cells dis-
sociate from the primary tumor site and migrate towards dis-
tant sites in the body. We then discuss the strengths and limi-
tations of conventional experimental approaches to reproduce
the complexity of cancer metastasis and the tumor microenvi-
ronment. Next, we review state of the art “on-chip” platforms
to study the role of the different physicochemical features of
the tumor microenvironment, in the various stages of the met-
astatic process. We conclude by providing future perspectives
on the incorporation of advanced bioactive materials, cell
reprogramming, and targeted genome editing into microfluidic
platforms, and how they can be used to improve on current ex-
perimental approaches for the study of cancer metastasis.
2. Overview of the metastatic process
Cancer metastasis is a remarkably complex and multi-
parametric process, comprised of sequential stages that make
up the so-called “metastatic cascade”.17 These stages include:
(1) dissociation of cells from the primary tumor (shedding), (2)
local invasion through the basement membrane and the extra-
cellular matrix (ECM), (3) entry into the blood or lymphatic ves-
sels (intravasation), (4) circulation through the lymphatic sys-
tem and the bloodstream, (5) arrest in the capillaries and
migration out of the vasculature (extravasation) into the second-
ary site (seeding), (6) formation of micro and macro-metastasis
in the target organs, and (7) induction of new blood vessels (an-
giogenesis) that will provide oxygen and nutrients to the meta-
static tumor18 (Fig. 1A). This complex succession of events also
presents several rate-limiting steps that could be pharmacologi-
cally targeted, as potential basis for therapeutic intervention.
For cancer cells to be able to metastasize to distant tissues,
they must possess migratory and invasive phenotypic traits.19
Although these features are acquired early during tumorigene-
sis, they must remain dynamic and adaptive throughout the
journey of migratory cells to the metastatic site. As cancer cells
spread, they must be able to selectively overcome different
types of environmental stresses, which include cytotoxic immu-
nity, low oxygenation, and the increased acidity that results
from enhanced cellular metabolism20,21 (Fig 1B). In addition,
recent evidence suggests that metastatic colonization can only
be achieved by rare tumor-initiating cells or cancer stem cells
(CSCs).22 CSCs are able to survive in the circulation, adapt to
new microenvironments at metastatic sites and re-initiate tu-
mor growth.22 Thus, the presence of CSCs within the migratory
tumor mass might strongly favor the formation of metastatic
tumors, which makes them an attractive target for therapy.
Apoptosis of migrating cells prior to their entry into the
metastatic site often prevents the spread of the majority of cir-
culating tumor cells (CTCs)23 (Fig. 1C). Malignant cells can in-
vade into multiple organs, where they could develop into met-
astatic tumors or remain dormant for extended periods of
time24,25 (Fig. 1D). Moreover, several studies have demon-
strated that cell and microenvironmental signaling can lead to
spontaneous regression in several types of primary and meta-
static cancers26–30 (Fig. 1E). This is a remarkably complex pro-
cess, modulated by several genetic, epigenetic, and cellular
factors, through the induction of apoptosis and immune sys-
tem activation, as well as the inhibition of matrix meta-
lloproteinases (MMPs) and angiogenesis.18 These observations
suggest that microenvironmental signaling at the metastatic
site could either lead to the temporal suppression of malig-
nancy, or to the re-activation of dormant metastatic cells.
The successful establishment of metastatic tumors relies
heavily on the cumulative ability of malignant cells to adapt
to different environments throughout the metastatic
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cascade.31 The molecular pathways and cellular interactions
that modulate the regression and dormancy of invading cells,
as well as those involved in their eventual re-activation, repre-
sent attractive targets for anti-metastatic drug development.
Therefore, the study of these and other aspects of cancer me-
tastasis will help identify relevant targets, which could poten-
tially be used to improve prognosis and treatment outcome.
3. Influence of the tumor
microenvironment on cancer
metastasis
The bi-directional communication between cancer cells and
the surrounding tumor microenvironment endows primary
tumor cells with the ability to proliferate, migrate, invade
and colonize distant tissues to establish metastatic tu-
mors.32 The tumor microenvironment refers to the actual
physiological setting that supports and modulates the pro-
liferation, function and fate of cancer cells. This complex
ecosystem comprises various soluble factors, nutrients, met-
abolic components, ECM proteins, and several non-
malignant cells that are supported by vascular networks
(Fig. 2). The cellular component of the microenvironment
consists primarily of stromal cells that are able to recruit
endothelial cells and fibroblasts, as well as leukocytes, as
well as leukocytes and other immune cells that constitute
the inflammatory component of the microenvironment
(Fig. 2A).33 Fibroblasts in particular are in close association
with cancer cells throughout all stages of tumorigenesis,
where they exert functional and structural roles including
the production of growth factors, chemokines, ECM pro-
teins, and remodeling enzymes that promote angiogenic re-
cruitment.34,35 The interaction between tumor cells and
Fig. 1 Overview of cancer metastasis. A. The metastatic cascade. Cancer metastasis involves the sequential progression of different stages, which
include: (1) dissociation of cells from the primary tumor (shedding), (2) local invasion through the basement membrane and the ECM (invasion), (3)
entry into blood or lymphatic vessels (intravasation), (4) circulation through the lymphatic system or the bloodstream (circulation), (5) arrest in
capillaries and migration out of the vasculature (extravasation) into the surrounding distant tissue (seeding), (6) formation of micro and macro-
metastasis in the target organs, and (7) induction of new blood vessels (angiogenesis). B. Cancer cell adaptability. Tumor-initiating mutations pro-
mote cancer cell survival by increasing their ability to overcome different environmental stresses (i.e., cytotoxic immunity, and hypoxic and acidic
environments). C. Death of metastatic cells. Apoptosis of migratory cells, immune surveillance in the circulation, and microenvironmental signaling
prevent the spread of the majority of circulating tumor cells. However, cancer stem cells are able to survive in the circulation and adapt to new
microenvironments at metastatic sites. D. Microenvironmental signaling modulates malignancy. The interplay between cancer cells and the new
metastatic microenvironment could promote the development of clinically relevant metastasis, or prevent further tumor growth by inducing dor-
mancy in invading cells. E. Modulation of tumor fate. Established metastatic tumors can induce the formation of new blood vessels that provide
them with oxygen and nutrients. However, genetic, epigenetic and microenvironmental factors can also lead to the spontaneous regression.
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these cancer-associated fibroblasts (CAFs) leads to epige-
netic alterations in the latter that disrupt the modulation
of cell division36,37 (Fig. 2B). In turn, CAFs are able to sup-
press the normal function of immune T cells in the micro-
environment, through the release of pro-inflammatory cyto-
kines such as IL-638,39 (Fig. 2C). Moreover, they are also
able to promote the upregulation of transcription factors
that are involved in epithelial-to-mesenchymal transition
(EMT)40,41 (Fig. 2D). During EMT, tumor cells undergo a
rearrangement of cytoskeletal organization and cell–cell
junctions, which results in the acquisition of migratory
abilities and the invasion of local and distant tissues.42,43
Recent evidence also suggests that the direct association
with the stroma, renders some populations of cancer cells
resistant to chemotherapeutic drugs.44 Hence, the study of
the interactions between tumor and stromal cells is crucial
to design more efficacious therapies, and to improve the ef-
fectiveness of current approaches.
The synergistic action of stromal and tumor cells also
leads to the active remodeling of the ECM (Fig. 2E). Re-
cent studies have demonstrated the role of the physical
properties of the ECM in the modulation of cancer metas-
tasis.45,46 Differences in ECM topology modulate meta-
static cell motility through physical cues that guide the
directionality of cell migration.47,48 Increased ECM stiff-
ness has been associated with the induction of stem cell
differentiation, modulation of cell adhesion, ECM deposi-
tion, and upregulation of genes that promote invasion
and metastasis.49,50 In addition, the higher mechanical re-
sistance associated with increased ECM stiffness could de-
termine the specific mechanisms used by metastatic cells
to invade the surrounding tissues.51 Similarly, ECM den-
sity has also been shown to influence the cooperativity be-
tween invasive tumor cells with mesenchymal pheno-
types.52 Therefore, the physical interactions of tumor cells
and their modulation by mechanical cues from the
Fig. 2 The influence of the tumor microenvironment in cancer metastasis. A. Inflammatory component. Cells from the immune system
infiltrate into the tumor site in response to chemotactic signals secreted by the microenvironment, where they not only fail to exercise anti-
tumor effector functions, but they are co-opted to promote tumor growth. B. Cancer-associated fibroblasts (CAFs). CAFs can originate from
multiple resident precursor cell types, including endothelial, smooth muscle, myoepithelial, and mesenchymal stem cells. They exert structural
and functional roles, which include the production of growth factors, ECM proteins, and remodeling enzymes that promote angiogenic recruit-
ment. C. Immune suppression. CAFs not only secrete pro-tumorigenic growth factors, but they also express pro-inflammatory gene signatures,
which induces neo-vascularization and recruitment of immune cells. D. Epithelial-to-mesenchymal transition (EMT). The tumor-associated
stroma and the hypoxic environment promote EMT at the primary site, which allows cancer cells to break free from epithelial cell–cell junc-
tions and acquire an invasive phenotype. E. ECM remodeling. The synergistic action of stromal and tumor cells leads to the active remodeling
of the physical properties of the ECM, such as matrix stiffness, pore size, and viscoelasticity. In turn, the topology of the ECM modulates cell
motility, tumor progression and metastasis. F. Mechanical cues. In order to migrate across a variety of environments, metastatic cells must be
able to alter their cell shape and squeeze through small gaps in the ECM, or extravasate into the blood or lymphatic vessels. Similarly, circulat-
ing tumor cells that enter into the bloodstream must tolerate several hemodynamic stresses, before they can extravasate to establish new
metastatic tumors.
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microenvironment are determinant to the progression of
the metastatic process (Fig. 2F).
The heterotypic interactions between cancer cells with the
tumor microenvironment leads to the recruitment of different
cell types, the modulation of cell fate, and the dynamic modifi-
cation of the physical features of the ECM. In turn, these modi-
fications influence cancer cell behavior, and trigger several
mechanisms associated with tumor invasiveness. Elucidating
the different types of microenvironmental cross-talk will pro-
vide a better understanding of the mechanisms that modulate
cancer cell metastasis, as well as their implications in patient
outcome and treatment. In addition, these advancements in tu-
mor and environmental mechanobiology also highlight the im-
portance of representing these interactions accurately, with the
use of adequate experimental models.
4. Strengths and limitations of
conventional models of cancer
Experimental models of cancer allow the dynamic visualization
of the evolution of the disease, as well as high-throughput and
reproducibility for hypothesis testing, drug screening, and bio-
marker discovery. To this date, the use of different in vitro and
in vivo tumor models has provided invaluable mechanistic in-
sight into different phenomena associated with cancer cell pro-
liferation and metastasis, ECM remodeling, tumor dormancy
and angiogenesis, as well as drug resistance. However, conven-
tional models of cancer exhibit several intrinsic shortcomings,
which limit their potential to study more complex phenomena
associated with human diseases.
4.1. Two-dimensional (2D) and three-dimensional (3D)
in vitro models
In vitro models are remarkably practical and can be designed
to incorporate various cell sources (e.g. patient cells, commer-
cially available cell lines, stem cells, stromal cells, immune
cells, etc.), biophysical properties (e.g. oxygen partial pres-
sure, pH, interstitial flow, etc.), ECM features (e.g. fiber den-
sity, stiffness, surface patterns, etc.), and biochemical stimuli
(e.g. chemoattractants, chemokines, angiogenic and growth
factors, etc.).8 In particular, 2D cultures have been widely
implemented in several different areas of fundamental and
applied cancer research, as well as in drug discovery and effi-
cacy testing, and translational studies. This large spectrum of
applications is strongly related to the low cost, reproducibil-
ity, accessibility, and ease of handling associated with 2D cul-
tures. However, the shape and fate of cells propagated under
2D conditions differ radically from those growing in 3D na-
tive tissues.53 This is particularly critical for the study of can-
cer biology, since cell morphology has been shown to deter-
mine cell behavior, signal transduction, responsiveness to
external stimuli, and resistance to radio- and chemotherapy
agents.54
Pre-clinical cancer research is usually carried out using 2D
cancer models. However, this simplified geometry translates
to variations in cell–cell and cell–ECM interactions that lead
to discrepancies in drug responses in vitro.55,56 Because of
this, 3D in vitro models have been increasingly used as an al-
ternative approach between 2D cultures of isolated cancer
cells, and in vivo models with higher complexities. Similar to
2D models, 3D culture systems can also be engineered to be
biomimetic, and to incorporate cancer cells alone or in
heterogeneous co-cultures. In particular, the spatially relevant
arrangements of 3D cultures help mimic native cellular inter-
actions, which promotes the acquisition of phenotypic fea-
tures associated with tumors in vivo. Comparative studies
have demonstrated that proteins associated with metabolism,
cell stress response, signal transduction, protein synthesis,
and cellular transport are over expressed in 3D tumor spher-
oids (tumorspheres), when compared to 2D cultures.57 Other
groups have also demonstrated that tumorspheres are com-
paratively more resistant to chemotherapeutic drugs, and
possess an increased number of CSC-like populations.58 Due
to its relevance to basic and clinical cancer research, several
methods have been developed to generate tumorspheres, in-
cluding spontaneous aggregation, rotary cell culture systems,
hanging drops, matrix encapsulation, magnetic levitation, 3D
bioprinting, as well as low binding and micro-patterned
plates.59 However, 3D spheroid models still present several
technical challenges, as well as intrinsic limitations to mimic
the more elaborate features of complex tissues.
4.2. In vivo animal models
Although organotypic 3D models are increasingly being used
in translational cancer research, the lack of more sophisti-
cated whole-organ culture systems still makes animal models
necessary for drug toxicity and efficacy validation. In vivo ani-
mal models have been used extensively to recapitulate the
natural history of human cancers, as well as their clinical re-
sponses to investigational anti-cancer therapies that have
shown promise in vitro.60–62 However, the use of animals for
experimentation is often restricted by the access to test sub-
jects and the feasibility of probing methodologies, as well as
the ethical concerns related to the discomfort and pain
inflicted on live subjects. In addition, in vivo models might
not be accurate enough to predict the efficacy of therapies di-
rected against certain types of human tissues.
Traditionally, rodents have been the most frequently used
animal models in cancer research, and have enabled the
study of human disease function in vivo. Among these, the
most common rodent cancer models are chemically or ge-
netically induced cancer models, and xenograft models.63 In
particular, xenograft cancer models are generated when hu-
man tumor cells are transplanted either under the skin (ec-
topic) or into the organ of origin (orthotopic) in immuno-
compromised animals.60 These models constitute a relatively
inexpensive approach for generating in vivo tumors, which
can be formed from human primary cells or established can-
cer cell lines. Because of this, xenografts are frequently used
for several purposes in drug discovery and development,
which include: characterization of disease pathophysiology,
evaluation of the mechanisms of action of existing drugs,
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discovery of new drug targets and biomarkers, establishment
of pharmacodynamic/pharmacokinetic relationships, estima-
tion of clinical dosing regimens, and determination of safety
margins and toxicity.53 However, they still exhibit dis-
advantages that often prevent the efficient translation of
novel research to the clinical setting. These are mainly associ-
ated with discrepancies in the effectiveness of anti-cancer
drugs and the lack of human stroma–tumor interactions, as
well as the absence of an immune component due to the
compromised immune systems of experimental animals.60
Despite their important contributions to cancer research, ani-
mal models still constitute imperfect representations of hu-
man disease, which often leads to errors in the selection and
approval of drugs in clinical trials. Furthermore, the highest
probability of attrition for all drugs used in oncology occurs
during the more costly phases II and III of clinical develop-
ment, which is a reflection of the limited clinical relevance
and predictive power of current pre-clinical models.61,63
More recently, microfluidic systems have been used in
conjunction with tissue engineering approaches and ad-
vanced biomaterials, in order to develop more sophisticated
platforms to successfully tackle the complexity of human can-
cers. These novel experimental platforms exhibit several tech-
nical and scientific advantages over conventional models of
cancer64 (Fig. 3). Furthermore, these “on-chip” systems can
be used to study treatment-induced responses at the tissue
and organ level for drug screening, while also allowing the
dissection of physiological complexities into more discrete
units to ease their analysis.
5. Microengineered models of the
metastatic microenvironment
All of the major events that are relevant to proliferation, sur-
vival, and metastatic spread of malignant cells, are depen-
dent on the interactions between the cellular and physico-
chemical components of the tumor microenvironment. Due
to their complexity, the study of these processes has been
majorly conducted using animal models. Recently, novel “on-
chip” cancer models have emerged as an efficient alternative
to conventional in vitro and in vivo approaches, since they
can recapitulate the native microenvironment of human tu-
mors in a comparatively simpler, more accurate, and human
relevant fashion. With the advent of microengineered sys-
tems, several studies have reported the application of these
novel platforms in different areas related to cancer cell biol-
ogy, including tumor cell detection, isolation and
characterization,65–68 modeling of cancer–immune interac-
tions,69 mechanics,70 drug screening and development,71,72
as well as the study of the tumor microenvironment.53,73–75
Similarly, several microfluidic systems have been developed
to study the dynamic events that constitute the metastatic
Fig. 3 Advantages of microfluidic models over conventional in vitro and in vivo models. Comparative schematic of the different types of models
that are available for fundamental cancer research and preclinical drug screening.
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process, including 3D invasion,76,77 intra- or extravasa-
tion,78,79 and angiogenesis.80,81
Two of the most remarkable aspects of microengineered
systems are: (i) the ability to integrate complex cell-based as-
says with real-time and non-invasive monitoring systems for
quantitative measurements of relevant cellular parameters,
and (ii) the ability to reproduce the complexity of the bio-
physical, biochemical and cellular components of the micro-
environment in human tumors. Moreover, the integration of
multiple microengineered components provides the unique
opportunity to monitor highly complex phenomena in real-
time, using non-invasive probing techniques. Thus, in the
next section we will review the most recent developments in
integrative microengineered platforms to study the roles of
various microenvironmental features, throughout the differ-
ent stages of cancer metastasis.
5.1. Models of cancer cell invasion
Cell invasion, the first step of cancer metastasis, involves the
adhesion, proteolysis, and migration of metastatic cancer
cells through the ECM. Throughout this process, cancer cells
engage in a bidirectional communication with their sur-
rounding microenvironment through both physical and bio-
chemical cues. Pro-inflammatory cytokines secreted by locally
activated stromal cells from the microenvironment, such as
TGF-β, TNF-α, and IL-6, are capable of inducing EMT in car-
cinoma cells and facilitate local invasion and metastatic dis-
semination.82 Although blockade of IL-6 signaling in pre-
clinical models has been proven to prevent tumor growth
and metastasis, its success in clinical trials has been lim-
ited.83 Therefore, identifying features that predict response to
anti-IL-6 therapy are needed. Recently, Lei et al. described
the development of a microfluidic device that incorporates
impedance measurement for the quantitative determination
of cell invasion, under biomimetic cytokine stimulation84
(Fig. 4Ai). This device consisted of two reservoirs connected
through a microchannel that mimicked the basement mem-
brane in vivo. Malignant NPC-BM1 cells were seeded in one
reservoir, and allowed to invade through a microchannel
filled with a methylcellulose hydrogel to another reservoir
(Fig. 4Aii). Electrodes embedded on the bottom of the micro-
channel allowed for impedance measurement of migrating
cells. Using this device, they investigated the influence of IL-6
cytokine signaling in cell invasion, which demonstrated that
invasion rates were directly proportional to the IL-6 concen-
tration82 (Fig. 4Aiii). The approach presented by Lei et al. en-
ables the quantitative study of cell invasion under extracellu-
lar biochemical stimulation, which might facilitate the
quantitative assessment of relevant clinical parameters in
translational cancer studies. More importantly, the design of
the device eliminates the influences of membrane pore size
and gravity, which are the major technical concerns associ-
ated with conventional Transwell invasion assays.
Biochemical signals from the tumor microenvironment
are mainly secreted by CAFs. However, the molecular mecha-
nisms by which CAFs influence tumor behavior are still not
fully understood. Recently, Yu et al. reported the engineering
of a microfluidic device for the 3D co-culture of non-small
cell lung carcinoma (NSCLC) cells and CAFs, to study the in-
teractions between tumor and stromal cells in the microenvi-
ronment85 (Fig. 4Bi). Normal human fibroblasts were first ac-
tivated to CAFs through their co-culture with A549 and SPCA-
1 lung cancer cells, and then CAFs-conditioned growth me-
dium was assessed for the promotion of NSCLC cell invasion
(Fig. 4Bii). Their results demonstrated that NSCLC cell migra-
tion in response to stromal signaling from CAFs was pro-
moted in part through the up-regulation of the stress-
induced chaperone protein GRP78. Interestingly, GRP78 is
significantly upregulated in various human cancers, where it
has been associated with tumor progression, evasion of apo-
ptosis, resistance to chemotherapy, and poor prognosis.86
The influence of stromal cells on the invasiveness of cancer
cells was also investigated in a recent study by Bischel et al.87
In this contribution, they described the integration of a
microfluidic co-culture of C4-2B prostate cancer and MC-3T3-
E1 bone marrow stromal cells, with a multi-photon imaging
component (Fig. 4Ci). They used this device to investigate the
mechanisms by which soluble signals from the microenviron-
ment were able to influence prostate cancer cell invasion
(Fig. 4Cii). Similar to the results described by Yu et al., the
work presented by Bischel et al. demonstrated that the cross-
talk between tumor and stromal cells led to the promotion of
cancer cell invasion. In particular, this enhancement in the
protrusive phenotype of prostate cancer cells, was shown to
be mediated by the increased activity of the polyamine cata-
bolic enzyme APAO (Fig. 4Ciii).
Tumorspheres have also been integrated in micro-
engineered models of tumor invasion. Recently, Choi et al.
developed a biomimetic microsystem that recapitulated the
3D structural organization of breast ductal carcinoma in
situ88 (Fig. 4Di). The co-culture was comprised of MCF10
breast tumorspheres in association with human epithelial
cells from the mammary duct, as well as human fibroblasts
embedded in a biomimetic scaffold. This culture system was
then integrated into a compartmentalized microfluidic sys-
tem that mimicked the native microarchitecture of the gland
(Fig. 4Dii). They investigated the application of their micro-
device as a drug screening platform, using the widely used
chemotherapeutic agent paclitaxel. Their results showed that
although the diameter of the spheroids remained unaltered,
the administration of the drug prevented invasion into the
surrounding stroma (Fig. 4Diii).
The approaches described in this section demonstrate the
application of microengineered systems to generate physio-
logical models of cancer invasion, which recapitulate the
functional and structural interactions of cancer cells with dif-
ferent cell types and soluble signals. However, cancer cell in-
vasion of the ECM is also promoted by local physical forces
in the microenvironment, such as the increased interstitial
fluid pressure (IFP). IFP is brought about by the collapse of
lymphatic vessels due to increased mechanical compression
from solid tumors, and has been shown to influence the
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Fig. 4 Models of cancer cell invasion. A. Microfluidic device for impedimetric monitoring of cell invasion. (i) Schematic of the experimental setup
for the invasion assay. The device was composed of a glass substrate embedded with 8 straight electrodes, and a poly(dimethylsiloxane) (PDMS)
layer with 2 reservoirs connected through a methylcellulose hydrogel; (ii) successive microscopic images of cell invasion, the red lines represent the
leading edges of cells at the corresponding time points; (iii) impedimetric monitoring of cell invasion under IL6 signaling, each series represent the
reading recorded once cells reached each electrode, positioned at the indicated distance (dash line: threshold) (reproduced with permission from
ref. 84). B. Microfluidic device to study CAF-mediated breast cancer cell invasion. (i) Schematic of the integrated microfluidic device for non-contact
cell co-culture and invasion. The device contained six chip units, with co-cultures of cancer and stromal cells to study cell invasion across a gradient
of cell-basement membrane extract. The panel also shows a representative image of the concentration gradient engineered across the biomimetic
ECM after 5 h; (ii) representative images of the effect of control and CAF-conditioned growth media on SPCA-1 and A549 lung cancer cell migration
(reproduced with permission from ref. 85). C. Microfluidic device to study the influence of the bone microenvironment on prostate cancer cell inva-
sion. (i) The schematic shows the process to generate the co-cultures of MC-3t3-E1 osteoblasts and prostate cancer cells for the invasion assays; (ii)
the schematic shows hypothesized mechanism by which osteoblasts interact with prostate cancer cells through the increased activity of ROS-
producing APAO; (iii) representative image of cells that developed protrusions into the collagen I hydrogel within the device. Scale bars: 50 μm
(reproduced with permission from ref. 87). D. Microfluidic biomimetic model of breast cancer invasion. (i) Schematic of the microarchitecture of the
breast cancer-on-a-chip microdevice. Both culture chambers are separated through a membrane that mimics the native basement membrane of
the gland. Tumor spheroids are seeded in the epithelial layer in the upper chamber, while the stromal layer embedded with fibroblasts is created on
the opposite side of the membrane; (ii) illustration of the tissular architecture of breast ductal carcinoma in situ (DCIS), within the mammary duct;
(iii) fluorescence imaging showing cross-sectional and 3D rendered views of DCIS spheroids (green) bound to the mammary epithelial cells (red).
Spheroids grow in association with human mammary fibroblasts (cyan) in the stromal layer. Scale bars: 100 μm; (iv) fluorescence micrographs of
DCIS spheroids without (left) and with (right) paclitaxel treatment. Scale bars: 100 μm (reproduced with permission from ref. 88).
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migratory behavior of cancer cells in 3D culture.89 Different
approaches, such as the one recently reported by Piotrowski-
Daspit et al., have demonstrated that IFP leads to pressure-
induced changes in genes that modulate cell invasion and
motility.90 Hence, microengineered invasion models that in-
corporate the influence of physical forces, could potentially
reveal molecular pathways or cellular responses that might
not be observed under static conditions.
5.2. Models of cancer cell trans-endothelial migration
Another critical event in the metastatic cascade occurs after
migratory cells invade the local stroma, and intra- or extrava-
sate the systemic circulation in a process referred to as trans-
endothelial migration. Cancers of epithelial origin, also re-
ferred to as carcinomas, are the most common type of cancer
observed in the clinic. The majority of human carcinomas
disseminate from the primary tumor into the interstitial
space, and eventually intravasate into lymphatic vessels
where they spread to distant sites in the body.91 However, the
cellular mechanisms by which cancer cells interact with the
lymphatic endothelium are still not fully understood. Re-
cently, Pisano et al. engineered a microfluidic system that
recreated the different types of physiological fluid forces oc-
curring at the tumor microenvironment (Fig. 5Ai). They used
this device in conjunction with image analysis to quantify cell
invasion and transmigration of MDA-MB-231 mammary ade-
nocarcinoma cells92 (Fig. 5Aii). Their results demonstrated
that luminal and transmural flows promote invasion and
transmigration of MDA-MB-231 cells across the ECM and the
biomimetic lymphatic endothelium (Fig. 5Aiii). The different
geometries integrated into this platform allowed mimicking
of the different compartments in lymphatic capillaries, as
well as their corresponding biomechanical cues. Moreover,
the integration of a standard invasion assay within a con-
trolled microfluidic system allowed the quantification of tu-
mor cell transmigration rates and dynamics, as well as their
rate of detachment from the endothelium. Hence, this study
not only provides new insight into the modulation of tumor
migration by fluid forces in the lymphatic microenvironment,
but it also presents a novel in vitro tool to study tumor
mechanobiology.
Cellular heterogeneity is a key characteristic of cancer cells
within the tumor mass that leads to subgroups of cells hav-
ing distinct growth advantages, and different migration and
metastatic capabilities.93 Conventional in vitro migration as-
says study invading cells at the population level, and do not
allow the recovery of migrating viable cells for analysis. This
could potentially mask intrinsic differences among individual
cells, which would limit their application as screening plat-
forms. To address this issue, Chen et al. engineered a single-
cell microfluidic platform to study the migration of individ-
ual MDA-MB-231 breast cancer cells, upon a hepatocyte
growth factor (HGF)-chemotactic gradient (Fig. 5Bi). HGF is a
multi-functional cytokine that is involved in embryogenesis,
organogenesis, adult tissue regeneration, and carcinogene-
sis.94 The approach presented by Chen et al. allowed the
post-migration collection and analysis of cells with varying
degrees of invasiveness95 (Fig. 5Bii). Furthermore, they incor-
porated choke points into the migration channels with di-
mensions similar to lymphatic capillaries in vivo, which
helped mimic the intravasation of tumor cells to the lymph
nodes (Fig. 5Biii). Isolation and propagation of highly chemo-
tactic and non-chemotactic cells revealed that the migratory
mesenchymal phenotype was heritable (Fig. 5Biv), and that
these cells overexpressed known migration and metastasis-
associated genes. In particular, this approach demonstrates
the remarkable potential of microengineered systems as
highly selective screening platforms that can be used to assay
and isolate individual cells, based on clinically relevant fea-
tures of heterogeneous cancer populations.
The entry of tumor cells into the bloodstream is an impor-
tant route for cellular metastasis to distant organs.96 Hence,
several microfluidic models that simulate 3D functional vas-
cular networks have been engineered to study cancer cell mi-
gration into the blood vessels.97 Wang et al. engineered a 3D
microsystem to model the transvascular migration of hepato-
cellular carcinoma HCCLM9 cells, through biomimetic and
tunable blood vessels that mimicked the native vasculature
and hemodynamic conditions98 (Fig. 5Ci). The engineered de-
vice consisted of transparent, elastic and porous cellulose-
based microtubes, lined with a 3D endothelium and
implanted into a biomimetic 3D collagen matrix. Their re-
sults demonstrated that endothelial cells were able to migrate
across the artificial blood vessel wall, and into the surround-
ing collagen matrix (Fig. 5Cii). In addition, they demon-
strated that HCCLM9 cells could successfully transverse the
biomimetic vasculature wall under HGF stimulation
(Fig. 5Ciii). The approach presented by Wang et al. demon-
strates the potential of microengineered systems to recapitu-
late physiological structures and parameters in vitro, such as
blood vessels and vascular hemodynamics, respectively.
Moreover, the successful reconstruction of a vascularized
microenvironment with transvascular migration under bio-
chemical signals, has strong implications for basic and trans-
lational research on tumor–vascular interactions.
After metastatic cells enter the systemic circulation they
must survive several stresses, which include hemodynamic
shear forces, immune surveillance, lack of substratum, and
entrapment in capillary beds.99 After this, metastatic cells
should be able to extravasate the circulation into the meta-
static site, and re-initiate tumor growth. Extravasation is a
critical event that constitutes an attractive target for diagnos-
tic and therapeutic intervention and yet, the precise mecha-
nisms that regulate this process remain unclear.100 In addi-
tion, despite efforts to model organotypic tumor
microenvironments, the mechanisms that drive the organ-
specificity of cancer metastases remain largely unresolved. In
a recent contribution, Jeon et al. engineered an organ-
specific microfluidic model to study breast cancer cell extrav-
asation, within a perfusable microvascularized bone-
mimicking microenvironment101 (Fig. 5Di). They used this
device to generate different biomimetic microenvironments,
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Fig. 5 Models of cancer cell trans-endothelial migration. A. Microfluidic model of the tumor–lymphatic interface in cancer cell migration. (i) Com-
parative schematic of interstitial (pink arrows), transmural (red arrows), and luminal (blue arrows) flows exerted on cancer cells (green) during inva-
sion across the interstitial–lymphatic interface; (ii) tumor cell transmigration rates across lymphatic epithelial cells (LECS) were calculated from the
appearance and disappearance of cells on the membrane (inner panel), Δ reflects the number of cells leaving the membrane; (iii) dynamics of inva-
sion and intravasation of MDA-MB-231 cells under luminal (LF) and transmural (TF) flows (reproduced with permission from ref. 92). B. Microfluidic
device for single cell migration. (i) Schematic of the device. Cells are seeded at the left side of the device and migrate through the channels towards
the right side following a chemoattractant gradient; (ii) representative images of the single-cell migration assay in response to HGF; (iii) variation in
the geometry of migration channels with the addition of choke points; (iv) scanning electron microscope images of a non-chemotactic vs. highly
chemotactic cell after retrieval (reproduced with permission from ref. 95). C. Microfluidic artificial blood vessel implanted tumor transvascular migra-
tion model. (i) Schematic of the artificial transvascular migration model. Cellulose/collagen artificial blood vessels are implanted in a collagen matrix
and seeded with endothelial cells to simulate the vasculature. Tumor cells are seeded in the collagen matrix to mimic transvascular migration; (ii)
schematic and fluorescence imaging of endothelial cell (EC) migration in response to VEGF; (iii) schematic and fluorescence imaging of intravasation
of HCCLM9 cells (red), in response to HGF. Scale bars: 50 μm (reproduced with permission from ref. 98). D. Microfluidic organotypic extravasation
assay. (i) Schematic of the device. Two lateral channels enable the addition of cancer cells, soluble factors, and the generation of flow across the
biomimetic vasculature in the gel channel. (EC: endothelial cells, MSC: mesenchymal stem cells, OB: osteoblast-differentiated cells, and CC: cancer
cells); (ii) schematic of the different vascular microenvironments that were investigated. (OD hBM MSC: osteoblast-differentiated MSCs, BMI ECM:
bone matrix, A3AR: adenosine bound to the A3 receptor) (reproduced with permission from ref. 101). E. Microfluidic assay for organ-specific metasta-
sis. (i) Schematic of the invasion assay. Circulating tumor cells (CTCs) were pumped over multiple artificial organs, including lung, liver, bone, and
muscle cells; (ii) fluorescence imaging of the adhesion of MCF7 and MDA-MB-231 cells to the endothelium. Scale bar: 200 μm; (iii) fluorescence im-
aging of metastatic inhibition by different concentrations of AMD3100. Scale bars: 200 μm (reproduced with permission from ref. 102).
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which they used to investigate the effect of antagonists of the
A3 adenosine receptor on extravasation, as well as the anti-
metastatic role of adenosine101 (Fig. 5Dii). In particular, the
approach presented by Jeon et al. constitutes a functional
heterocellular culture system, in which human breast cancer
cells are able to attach to and metastasize across a vascular
network. Thus, this platform is a remarkable example of how
microengineered systems can be used to mimic the pro- or
anti-metastatic signatures of different microenvironments, in
order to study cancer cells in controlled, organ-specific, phys-
iological conditions.
More recently, Kong et al. developed a microfluidic model
of multiple-organ invasion of CTCs. This platform allowed
the study of the metastatic spread of human MCF7 and MDA-
MB-231 breast adenocarcinoma, and ACC-M cystic adenocar-
cinoma cells to primary mouse cultures established from dif-
ferent organs102 (Fig. 5Ei). Using this approach, they demon-
strated that the three tested tumor cell lines exhibited a
significantly higher tropism to lung, liver, and bone marrow
tissues, when compared to muscle (Fig. 5Eii). Interestingly,
this behavior was consistent with results observed in experi-
ments using nude mice models, as well as the reported clini-
cal behavior of these cancers. Moreover, they used their de-
vice to perform comparative studies of the ability of different
concentrations of the CXCR4-antagonist AMD3100 to prevent
metastasis, both in vitro and in vivo. Their results demon-
strated that AMD3100 was able to prevent metastasis to the
lung by preventing the adhesion of CTCs to the endothelium
in vivo, a process which was efficiently mimicked by the
microfluidic model in vitro (Fig. 5Eiii). Interestingly, the simi-
larities in the results obtained with the microfluidic system
and those obtained in vivo, indicate that these type of ap-
proaches could eventually be used in preclinical tests to as-
sess the ability of anti-cancer compounds to prevent organ-
specific metastasis.
5.3. Models of tumor angiogenesis
After metastatic cells escape the systemic circulation and in-
vade into the parenchyma of the target organ, they either re-
main dormant or proliferate and develop into micrometastasis.
As metastatic tumors grow, they undergo a process known as
angiogenic switch, which refers to the progression from a non-
angiogenic state towards the active growth of new blood vessels
promoted by the vascular endothelial growth factor (VEGF).103
The conventional notion of angiogenesis stipulates that tumor
cells induce vessel growth in collaboration with the neighbor-
ing stroma. However, as additional mechanisms of tumor vas-
cularization have been identified, the specific pathways that
lead to the formation of the tumor vasculature are not fully un-
derstood.104 Chung et al. engineered one of the first platforms
to quantify cell migration and capillary morphogenesis, using a
3D collagen scaffold that integrated biochemical and biome-
chanical stimuli105 (Fig. 6Ai). This system was used to monitor
tumor cell-induced endothelial cell migration and angiogenesis
in real-time (Fig. 6Aii). More recently, Lee et al. used a similar
approach to quantify tumor cell angiogenesis, by further inte-
grating the ability to monitor transendothelial migration106
(Fig. 6Bi). Microvessel formation in this device was achieved
through vasculogenic stimulation of endothelial cells by fibro-
blasts. This resulted in smooth and continuous vessel bound-
aries that closely mimicked in vivo conditions (Fig. 6Bii). After
microvessel formation, U87MG glioblastoma cells were intro-
duced into the perivascular region, where they secreted angio-
genic factors that induced the formation of angiogenic sprouts.
In this contribution, Lee et al. explored the implementation of
this device as both, a cancer angiogenesis assay to test the anti-
VEGF effect of the drug bevacizumab, as well as a cancer intra-
vasation assay to test the pro-angiogenic effect of TNF-α
(Fig. 6Biii). Moreover, this platform could also be used to study
cancer cell or leukocyte extravasation, mechanotransduction of
endothelial cells to the intraluminal flow, as well as for selec-
tive retrieval of invading cancer cells for analysis. In particular,
this approach demonstrates how normal physiological pro-
cesses can be reproduced in vitro, in order to engineer biomi-
metic tissues that can be used for experimentation. In turn, the
generation of physiological structures that closely resemble hu-
man tissues will also help develop more accurate preclinical
models of human disease.
In a recent study, Theberge et al. engineered a micro-
fluidic system to study the effects of soluble factor signaling
on endothelial tubule formation.107 Using this system, they
investigated the effect of incorporating human macrophages
to co-cultures of endothelial cells and fibroblasts, in an ar-
rangement that enabled soluble factor communication be-
tween them (Fig. 6Ci). This is relevant because macrophages
are important mediators of angiogenesis, and act as a cellular
link that spatially and temporally connects angiogenesis with
lymphangiogenesis.108 Using this system, Theberge et al.
showed that the macrophage-secreted factor MMP12 was able
to suppress microtubule formation and angiogenesis
(Fig. 6Cii and Ciii). More importantly, this approach was sen-
sitive enough to resolve the dose-dependent nature of the
anti-angiogenic action of MMP12, a response which was
completely missed in more simplified assays.
The platforms described in this section could be used for
fundamental studies of the mechanisms that modulate physi-
ological angiogenesis, as well as screening platforms to test
potential anti-angiogenic compounds. In particular, the im-
plementation of microengineered systems for drug screening
would be greatly favored by their enhanced physiological rele-
vance and accuracy, when compared to conventional in vitro
approaches. However, key challenges to current systems
would first need to be addressed, which are mainly related to
the precise modulation of mechanical and biochemical fac-
tors to achieve physiologically-relevant conditions, (ii) en-
hancing the biomimicry of the engineered microvasculature,
and (iii) integrating the role of intraluminal and interstitial
flows in the microcirculation.
5.4. Models of the physical features of the microenvironment
In addition to cellular and biochemical cues, the actual phys-
ical interactions of tumor cells with their neighboring tissues
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Fig. 6 Models of tumor angiogenesis. A. Microfluidic device for capillary morphogenesis. (i) The schematic shows the set-up for the cell migration
assay. The arrangement of the device enables the direct comparison of endothelial cell migration (middle), triggered by chemotactic signals from
two side channels with different experimental conditions. The three channels are separated by a collagen scaffold (brown channels); (ii) represen-
tative images of HMVEC cell migration, in response to the chemo-attractant effect of MTLn3 breast cancer and U87MG glioblastoma cells in co-
culture (reproduced with permission from ref. 105). B. Microfluidic model of angiogenesis and intravasation. (i) Design scheme and experimental
procedures: (top left) schematic drawing of the microfluidic chip, (top right) microvessel formation, (bottom left) cancer angiogenesis assay, (bot-
tom right) cancer intravasation assay (LF: lung fibroblasts); (ii) time-lapse micrograph of microvessel formation. Endothelial cells scattered in the
vessel channel fuse together with a patent, perfusable lumen; (iii) micrograph of the microvessel wall after injection of U87MG cancer cells, and
cancer cells + bevacizumab (reproduced with permission from ref. 106). C. Microfluidic model of biomolecular angiogenesis. (i) Schematic showing
the two culture channels for seeding macrophages, and the HUVEC + normal human dermal fibroblasts (NHDF) mixture, which are connected by a
series of communication channels to allow soluble factor signaling. The schematic also shows the device workflow for seeding and differentiation
of THP-1 monocyte cell line to macrophages, polarization, seeding of HUVEC-NHDF mixture, and immunocytochemistry analysis. (Green: CD31,
blue: DAPI); (ii) endothelial cells form tubules in co-culture with fibroblasts. Tri-culture with macrophages prevents tubule formation, which is res-
cued by the addition of an MMP12 inhibitor. (iii) In co-cultures of endothelial cells and fibroblasts, tube formation is decreased by the addition of
exogenous MMP12, and partially rescued by the addition of an MMP12 inhibitor (reproduced with permission from ref. 107).
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are key determinants of the metastatic process.109 Through-
out the entry, circulation and escape of metastatic cells from
the circulation, they undergo deformation and hemodynamic
forces that affect their viability, as well as their ability to es-
tablish metastatic tumors.109 However, the relationships be-
tween hemodynamic forces and cancer cell viability, prolifer-
ation, motility, deformation, and interaction with the
endothelium are not fully understood. To investigate these
aspects of cancer metastasis, Huang et al. engineered a
microfluidic extravasation model that mimicked the mechan-
ical and biochemical microenvironmental cues from the vas-
culature110 (Fig. 7Ai). They used this device to study the indi-
vidual and synergistic effects of mechanical (i.e., fluid shear
stress and cyclic stretch) and biochemical stimuli (i.e., TNF-α
signaling) on the behavior of cervical adenocarcinoma HeLa
cells. Their results demonstrated that mechanical strain
could promote TRAIL-induced apoptosis in cancer cells, and
influence their adhesion to the endothelium (Fig. 7Aii). The
incorporation of TNF-α further promoted tumor cell adhe-
sion to the endothelium, which was weakened by the action
of this cytokine (Fig. 7Aiii). In addition, they also investigated
the potential of this system as a screening platform to evalu-
ate the antioxidant effect of platinum nanoparticles (Pt-
NPs).111 Their results demonstrated that Pt-NPs effectively re-
covered the integrity of the biomimetic endothelium, and de-
creased the number and spreading area of adhered tumor
cells. The work presented by Huang et al. exemplifies the in-
corporation of multiple physicochemical stimuli into a single
device that can be used to model physiological features of hu-
man tumors. However, the low-throughput of this approach
could limit its application as a platform for screening large li-
braries of candidate anti-metastatic compounds. To address
this issue, Spencer et al. recently developed a high-
throughput mechanofluidic system to study cancer cell adhe-
sion to the endothelium, the ECM, and platelets when
subjected to physiological levels of shear stress (Fig. 7Bi).112
Using this platform, they screened the effect on cancer cell
adhesion of various anti-inflammatory compounds, as well as
integrin and kinase inhibitors. Their results demonstrated
that inhibitors of the FLT-3 and AKT pathways were able to
selectively block cancer cell adhesion, while also exerting
minimum effect in the adhesion of leukocytes to endothelial
cells. In a follow-up work, they further interfaced their
mechanofluidic platform with cell-substrate impedance sens-
ing, which enabled the label-free evaluation of cell adhesion
under flow with high-throughput and in real-time (Fig. 7Bii).113
Using this improved version of their platform, they scre-
ened the effect of small molecule inhibitors on the adhesion
kinetics of breast cancer cells. Taken together, the results
presented by Spencer et al. demonstrated that there are
marked discrepancies in the data obtained in static condi-
tions, when compared to cell adhesion assays performed un-
der physiological shear stress (Fig. 7Biii). Moreover, their
screening process revealed that some compounds might pro-
mote cancer cell adhesion even if they also inhibit their pro-
liferation. This property demonstrates the remarkable utility
of microengineered devices as predictive models to screen
out compounds with undesirable properties, prior to exhaus-
tive and expensive pre-clinical studies.
Metastatic cells also adapt their migratory mechanisms
across the basement membrane and ECM in response to their
exposure to varying levels of physical confinement.114 Nuclear
deformation often limits migration across confined environ-
ments, due to the particularly large size and stiffness of cellular
organelle.115 In order to study the physical limitations of cancer
cell translocation, Malboudi et al. engineered a microfluidic de-
vice to evaluate the ability of MDA-MB-231 breast carcinoma
cells to alter their shape when migrating across gaps of differ-
ent sizes116 (Fig. 7Ci). The device consisted of an open chamber
connected to a main channel through perpendicular micro-
channels of different widths (Fig. 7Cii). Cancer cell transloca-
tion and migration across the microchannels were triggered by
a serum-induced chemotactic gradient, and the process could
be visualized in real-time (Fig. 7Ciii). Their results showed that
the physical limit for constriction and migration of MDA-MB-
231 cells in a confined setting was reached at the 7 μm width
microchannels. The approach presented by Malboudi et al.
could be further used to study the morphological changes in
the cytoskeleton and the nucleus that occur during migration
across a chemotactic gradient. More recently, Liu et al. also
engineered a microfluidic system to evaluate the ability of can-
cer cells to migrate through micro-constrictions, effectively
mimicking cell perfusion through the circulatory system during
metastasis117 (Fig. 7Di). In this study, Liu et al. described a
novel cellular parameter called “transportability”, which is de-
termined by cell stiffness and the frictional properties of the
cell surface. They demonstrated the ability of their device to
achieve precise, high-throughput separation of different breast
cancer cell lines, based on their size and transportability
(Fig. 7Dii). Furthermore, they found that treatment with the tu-
mor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA)
could enhance the transportability of cancer cells (Fig. 7Diii), a
response that also correlated with the up-regulation of CSC
markers (Fig. 7Div). This approach could potentially be used to
isolate and study populations of cells based on their mechani-
cal phenotype, as well as to study the correlation with their bio-
physical and invasive properties and expression of relevant
biomarkers.
In addition to the physical properties of the cell mem-
brane and the nucleus, the stiffness of the ECM also pro-
vides mechanical cues that are involved in cancer metastasis.
In a recent study, Garcia et al. engineered a microfluidic sys-
tem that could generate stable, linear and diffusive bio-
chemical gradients in polyacrylamide hydrogels, which pos-
sessed an additional perpendicular stiffness gradient118
(Fig. 7Ei). Using the non-cancerous MDCK canine cell line as
a model, they validated their approach by investigating the
cross-talk between a biochemical HGF-derived gradient and a
physical stiffness gradient. Their results revealed that cell
scattering was directly dependent on the synergy between the
two gradients (Fig. 7Eii and Eiii). Previous works have al-
ready studied the biophysical interactions between tumor
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Fig. 7 Models of the physical features of the microenvironment. A. Microfluidic model of the physicochemical cues from the vascular
microenvironment. (i) The layered composition of the device enabled the deformation of the seeded cells in the elastic membrane, when vacuum
is applied to the system; (ii) fluorescence imaging of the adhesion of the tumor cells (HeLa, green) on the endothelial monolayer (HUVEC, orange)
under physiologically-relevant mechanical conditions; (iii) tumor cells–endothelium interaction in a TNF-α conditioned environment. Fluorescence
imaging of tumor cells adhered to the endothelial monolayer, and their morphological changes in the presence of TNF-α. Scale bars: 20 μm
(reproduced with permission from ref. 110). B. Microengineered mechanofluidic platform for cell adhesion under flow. (i) The design of the device
was based on a 96-shaft gearbox, coupled to a standard 96-well culture plate. The panel also shows the overall process for detachment assays; (ii)
schematic of the label-free adhesion measurement system; (iii) adhesion of strongly metastatic MDA-MB-231 and moderately metastatic MCF-7
cells, under static (left) and flow (right) conditions (reproduced with permission from ref. 112 and 113). C. Microfluidic device for cancer cell defor-
mation. (i) The design consisted of an open chamber connected to a main channel through perpendicular microchannels of different widths. Cells
in the reservoir are allowed to migrate through the microchannels in response to FBS; (ii) representative phase contrast images of migration, which
shows that cells in the device are able to project into the microchannels independently of their width. (iii) Representative kymographs of individual
translocating cells (reproduced with permission from ref. 116). D. Microfluidic device for transportability. (i) The device consisted of a deterministic
lateral displacement microarray (left), and a trapping barrier microarray (right); (ii) quantification of the average transportability of six breast cancer
cell lines; (iii) transportability versus cell diameter is plotted for MCF-7 and TPA-induced MCF-7 cells. Black and blue circles indicate the 80% confi-
dence interval centered at the mean depicted by a green dot; (iv) western blot analysis of biomarker expression in MCF-7 and TPA-induced MCF-7
cells (reproduced with permission from ref. 77). E. Microfluidic model of biochemical and substrate stiffness gradients. (i) The chemical and me-
chanical gradients in the device were generated within a buried channel, which was located beneath a Y-shaped channel perpendicular to the an-
gle of the flow; time evolution of (ii) cell velocity and (iii) scattered distance for the MDCK cell migration assay. The direction of the HGF and stiff-
ness gradients for each of the 6 regions formed in the device are shown in the inner panels (reproduced with permission from ref. 118).
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cells and the ECM. For example, Pathak et al. engineered a
platform based on microfabricated polyacrylamide channels,
with defined wall stiffness and geometry.119 Using this sys-
tem, they were able to determine that cells migrating
through narrow channels moved faster than those in wide
channels and 2D surfaces, due to an enhanced polarization
of cell–ECM traction forces. The approach presented by
Garcia et al. is the first to integrate substrates with tunable
stiffness, as well as the spatial distribution of soluble bio-
chemical factors. However, further iterations of this ap-
proach should explore the incorporation of human cancer
cell lines or primary tumor cells in order to enhance its phys-
iological relevance.
Integrative platforms that incorporate stimuli form soluble
biochemical signals and physical substrate cues, can be used
to generate more sophisticated microenvironments with en-
hanced biomimicry. For example, one approach reported pre-
viously by Huang et al., described the patterning of different
cell-laden hydrogels to generate continuous interfaces, as well
as chemically and mechanically tailored 3D cellular niches.120
More recent studies are beginning to explore the generation
of responsive matrixes, through native deposition and assem-
bly of ECM proteins by human cells cultured under hydrody-
namic and biochemical stimulation.121 Next-generation
mechanotransduction platforms could be particularly useful
to study more dynamic phenomena, such as the ECM remod-
eling carried out by migratory cells. For example, a recent
contribution by Rahman et al. focused on cell migration
through ECM “microtracks”, which are tube-like features that
are formed through the proteolytic degradation of the
ECM.122 Using this platform, they determined that the focal
adhesion molecule vinculin played a critical role in
maintaining unidirectional migration of MDA-MB-231 cells
through microtracks. However, this approach did not take
into account the chemoattractant effect of biochemical or ox-
ygen gradients on the directionality of cancer cell migration.
Thus, future works should continue to address the synergy
between the physical features of the ECM, and the physico-
chemical gradients present in the tumor microenvironment.
5.5. Models of tumor hypoxia
Another aspect of tumorigenesis that is independent of cellular
or biochemical factors is the insufficient tissue oxygenation at
the tumor site, also referred to as hypoxia. Solid tumors exhibit
hypoxic regions due to the rapid growth of cells, whose oxygen
and nutrient demands exceed those supplied by the associated
vasculature. Furthermore, the overexpression of hypoxia induc-
ible factors such as HIF-1 promotes the expression of a series
of hypoxia-inducible genes, which leads to cancer cell invasion
and metastasis.123 To investigate the influence of hypoxic con-
ditions in the promotion of metastasis, Acosta et al. engineered
a microfluidic invasion assay that integrated a co-culture of
cancer and endothelial cells in a collagen matrix, with a system
Fig. 8 Models of tumor hypoxia. A. Microfluidic device of chronic and intermittent hypoxia. (i) The schematic shows a cross-section of the device
indicating the cell and vascular channels connected through a collagen matrix, as well as the gas channels used for delivery of the hypoxia and
normoxia gas mixtures; (ii) map of oxygen concentrations at steady-state within cross-section of the microfluidic device. The oxygen content in
the hypoxia and normoxia channels is 1% and 21%, respectively. Scale bar: 400 μm; (iii) phase contrast image of PANC-1 cells within the micro-
fluidic device during culture under the O2 gradient. Scale bar: 100 μm (reproduced with permission from ref. 124). B. High-throughput microfluidic
device for hypoxia-driven invasion. (i) Bright-field micrograph shows the arrangement of the device micro-chambers, as well as the established
chemotactic gradient. Each chamber has an upper chemoattractant reservoir that is connected to a cell culture chamber through parallel migra-
tion microchannels; (ii) the graphs show the percentage of migration and migrated distance (migratory potential) of SUM-159 cells, under
normoxic and hypoxic environments; (iii) comparison between the migrated distance and the percentage of migratory cells from samples corre-
sponding to different depths within the tumor (reproduced with permission from ref. 127).
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for temporal and spatial oxygen control (Fig. 8Ai). Using this
device, they were able to establish long-term (up to 8 days) cul-
tures of PANC-1 pancreatic adenocarcinoma cells, in a collagen
scaffold with oxygenation gradients consistent with chronic
and intermittent hypoxia124 (Fig. 8Aii). They investigated the
potential of their device to study cancer cell invasion in re-
sponse to different oxygen gradients. Invasion of PANC-1 cells
across the biomimetic collagen barrier occurred in response to
variations in the oxygen partial pressure, from 21% (ambient)
to 1% (hypoxia) (Fig. 8Aiii). The approach developed by Acosta
et al. enabled the long-term culture of cells in spatial oxygen
gradients and dynamically changing hypoxic microenviron-
ments. Thus, this approach has remarkable potential to study
not only tumor growth, but also normal developmental pro-
cesses that are influenced by hypoxia,125 as well as other non-
malignant diseases.126
Hypoxia has also been involved in the promotion of EMT
and metastasis through its synergistic action with tumor aci-
dosis. Recently, Zhang et al. engineered a high-throughput
microfluidic platform with a controlled oxygen microenvi-
ronment, and used it to study mesenchymal-mode migration
of SUM-159 breast carcinoma cells under hypoxia127
(Fig. 8Bi). Their results demonstrated that the distance mi-
grated, and the percentage of migratory SUM-159 cells was
consistently greater under hypoxic conditions (Fig. 8Bii).
They also investigated the potential of the engineered device
as a screening platform, using the small-molecule com-
pounds linifanib and 227013, as well as the HIF-1α inhibitor
2-MeOE2. Using this approach, they were able to identify
phenotypic differences in primary cancer cells isolated from
different areas of the tumor, mainly with respect to their via-
bility and migratory velocity (Fig. 8Biii). In particular, the ap-
proach presented by Zhang et al. could be used to assay the
migratory potential of samples with particularly low cell
numbers under tunable oxygenation conditions. Moreover,
the high-throughput of this platform enables its implemen-
tation as a screening platform to evaluate the efficacy of
anti-metastatic compounds.
6. Future perspectives
Although several applications of microengineered systems have
been described in the context of cancer research, the dyna-
mism and plasticity of these platforms hold remarkable poten-
tial for anti-metastatic drug research and development. Meta-
static cells engage in heterotypic interactions with different
tissue-specific microenvironments, as they migrate from the
primary tumor site to a target organ. Hence, therapeutic inter-
vention at any of the different stages of the metastatic cascade
holds significant promise for cancer patients with, or at risk of
metastatic disease. The multi-parametric nature of the meta-
static process, together with the remarkable heterogeneity of
human cancers demonstrate the need for high-throughput
screening platforms for drug discovery. Nevertheless, the trans-
lation of microengineered assay systems to high-throughput
testing presents additional challenges, which include: (i) the
miniaturization and automation of platform components, (ii)
straight-forward interfacing with standard probing and scale-
up technologies, (iii) the precise integration of large numbers
of cells into complex configurations, and (iv) the lack of versa-
tile cellular scaffolds and device materials.128 Theoretically, the
volume for each assay unit in microfluidic cell-based screening
systems could be scaled down to the submicroliter level, which
would translate to assays based on hundreds or even single
cells.129 However, one major drawback of such approach would
be that the inclusion of too few cells might impair cellular
microarchitecture, which in turn would reduce the predictive
power and physiological relevance of the assay. Moreover, next-
generation microengineered platforms could also allow the
modular integration of different organs-on-chips arrays, to ac-
count for the cross-talk between different tissues in vivo and
their contribution to disease progression. Nevertheless, future
progress will not solely rely on the capacity to manufacture and
scale-up physiologically relevant assays, but also on the adapta-
tion and development of readout techniques and probing
methodologies. In summary, the industrial scaling of cell-
based systems with such degrees of complexity like the ones
described in this review still presents many technical and oper-
ational compromises, and several technological challenges re-
main to be solved. Thus, despite the high-throughput capabili-
ties of some of these devices, they are still unlikely to be widely
extrapolated into the actual clinical context at their current
level of development. However, the enhanced physiological rel-
evance of these platforms could be used today to bridge the
gap between conventional in vitro and in vivo models, in order
to produce more accurate data and screen out non-effective
candidate compounds prior to extensive animal and human
trials.130
One of the most critical areas of opportunity for micro-
engineered cell-based assays is the incorporation of human pri-
mary tumor cells. This strategy would allow the generation of
more clinically relevant assays that are able to account for
inter-patient and inter-tumor heterogeneity. Primary and
established cell cultures could also be further tailored through
site-specific genome targeting, in order to evaluate the effect of
sequence-specific modifications on cancer cell phenotypes, as
well as screening of therapeutic efficacy in biomimetic environ-
ments.131 The engineering and incorporation of smart biomate-
rials will also help enhance the biomimicry of 3D cultures for
long-term modeling and assay of tissues with increased levels
of sophistication, as well as develop durable prophylactic and
therapeutic anti-cancer agents.132 Next-generation micro-
engineered devices should be used to investigate complex fun-
damental aspects of tumor malignancy, such as the microenvi-
ronmental promotion of tumor dormancy and regression. In
addition, the engineering of patient-specific metastasis-on-a-
chip platforms could one day eliminate the need for animal
models, while also enabling the opportune design of tailored
and molecularly-targeted therapies. Ultimately, incorporating
multiple organ- and tumor-on-chip approaches will provide un-
precedented insight into the interplay between normal and
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cancer tissues, which underlie the development and progres-
sion of metastasis.
7. Concluding remarks
State of the art microengineered systems allow the precise
and dynamic control of microenvironmental parameters that
are critical in the establishment of the clinical behavior of
metastatic tumors. These parameters include soluble and
physical cues from the tumor associated stroma, hetero-
cellular interactions of migratory cancer cells with surround-
ing tissues, physical stresses inflicted on CTCs during trans-
endothelial migration, and physicochemical gradients that
direct cell motility and invasion. Microengineered devices al-
low the real-time and non-invasive monitoring of cell-based
assays with tissue- and organ-level complexity. Their imple-
mentation in several areas of fundamental and translational
cancer research provides the unique opportunity to dissect
and recreate remarkably complex physiological processes,
with a level of human-relevance and precision that cannot be
achieved by conventional methods. As cancer therapeutics be-
gin to shift to personalized and molecularly-targeted ap-
proaches, the robustness and predictive power of micro-
engineered devices will undoubtedly impact the way in which
the preclinical evaluation of novel compounds is conducted.
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